Journal of Global Infectious Diseases

: 2011  |  Volume : 3  |  Issue : 1  |  Page : 63--72

Combination vaccines

David AG Skibinski1, Barbara C Baudner1, Manmohan Singh2, Derek T O'Hagan2 
1 Novartis Vaccines, Via Fiorentina 1, Siena, Italy
2 Novartis Vaccines, Cambridge MA, USA

Correspondence Address:
David AG Skibinski
Novartis Vaccines, Via Fiorentina 1, Siena

The combination of diphtheria, tetanus, and pertussis vaccines into a single product has been central to the protection of the pediatric population over the past 50 years. The addition of inactivated polio, Haemophilus influenzae, and hepatitis B vaccines into the combination has facilitated the introduction of these vaccines into recommended immunization schedules by reducing the number of injections required and has therefore increased immunization compliance. However, the development of these combinations encountered numerous challenges, including the reduced response to Haemophilus influenzae vaccine when given in combination; the need to consolidate the differences in the immunization schedule (hepatitis B); and the need to improve the safety profile of the diphtheria, tetanus, and pertussis combination. Here, we review these challenges and also discuss future prospects for combination vaccines.

How to cite this article:
Skibinski DA, Baudner BC, Singh M, O'Hagan DT. Combination vaccines.J Global Infect Dis 2011;3:63-72

How to cite this URL:
Skibinski DA, Baudner BC, Singh M, O'Hagan DT. Combination vaccines. J Global Infect Dis [serial online] 2011 [cited 2022 Aug 12 ];3:63-72
Available from:;year=2011;volume=3;issue=1;spage=63;epage=72;aulast=Skibinski;type=0